Overview QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine Status: Withdrawn Trial end date: 2019-08-23 Target enrollment: Participant gender: Summary This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with advanced, unresectable, and untransplantable HCC. Phase: Phase 1/Phase 2 Details Lead Sponsor: ImmunityBio, Inc.NantKwest, Inc.Treatments: Albumin-Bound PaclitaxelAvelumabCapecitabineCetuximabCyclophosphamideFluorouracilLeucovorinPaclitaxelSorafenibVaccines